biostudies-literatureLucas JTNational Cancer InstituteAmerican Lebanese Syrian Associated CharitiesNCI NIH HHS1166-1175https://www.ebi.ac.uk/biostudies/studies/S-EPMC9248404biostudies-literatureUnknown24(7)<h4>Background</h4>We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.<h4>Methods</h4>One hundred and fifty-five pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of adjuvant radiotherapy (RT) and dose-intense chemotherapy with autologous stem cell transplant. Craniospinal radiotherapy to 23.4 Gy (average risk, AR) or 36-39.6 Gy (high risk, HR) was followed by conformal RT with a 1 cm clinical target volume to a cumulative dose of 55.8 Gy. Subgroup was determined using 450K DNA methylation. Progression was classified anatomically (primary site failure (PSF) +/- distant failure (DF), or isolated DF), and dosimetrically.<h4>Results</h4>ThirtyNeuro-oncologyRevised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.PMC9248404P30 CA021765R25 CA023944Harreld JHKlimo PHuang JNorthcott PAEllison DWOnar-Thomas ARobinson GWTinkle CLTumlin PMerchant TELucas JTBecksfort JBSrinivasan SBoop FAOrr BAKrasin MJGajjar AfalseRevised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.<h4>Background</h4>We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.<h4>Methods</h4>One hundred and fifty-five pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of adjuvant radiotherapy (RT) and dose-intense chemotherapy with autologous stem cell transplant. Craniospinal radiotherapy to 23.4 Gy (average risk, AR) or 36-39.6 Gy (high risk, HR) was followed by conformal RT with a 1 cm clinical target volume to a cumulative dose of 55.8 Gy. Subgroup was determined using 450K DNA methylation. Progression was classified anatomically (primary site failure (PSF) +/- distant failure (DF), or isolated DF), and dosimetrically.<h4>Results</h4>Thirty2022-01-01T00:00:00Z2022 Jul2025-04-22T11:17:07.821Z2025-04-05T23:54:09.392ZS-EPMC92484043489426210.1093/neuonc/noab284